



knownwell

Latest Trends in Obesity Medicine

Angela Fitch, MD, FACP, Dipl. ABOM

Chief Medical Officer, Co-Founder knownwell

President Obesity Medicine Association

drfitch@knownwell.health



Obesity is a serious, treatable chronic disease



OBESITY

IS A SERIOUS CHRONIC TREATABLE DISEASE

Obesity

- a disease in which excess body fat has accumulated in a dysfunctional manner to a level that may have an adverse effect on health.

It's ultimately about biology, not BMI

BMI is a tool used in screening and diagnosis

- | | |
|---------------------|---------------|
| • Pre-obesity | BMI 25-29.9 |
| • Class 1 obesity | BMI 30-34.9 |
| • Class 11 obesity | BMI 35-39.9 |
| • Class 111 obesity | BMI \geq 40 |



Other such diseases are treated comprehensively...

Cardiovascular disease:
primary care, cardiology,
interventional cardiology,
cardiac surgery


Cancer: primary care,
oncology, radiation
oncology, oncology
surgery

Obesity: disjointed care
in silos, bariatric surgery,
obesity medicine, primary
care



Goals of obesity treatment

New medications: treating ABCD/Obesity to target






There is a clear best practice in treating obesity

Increasing health risks
Increasing adiposity



BMI > 40
BMI > 35 with
comorbidity




Surgery

20-40% weight loss

Endoscopic Procedures

10-20% weight loss

BMI > 30
BMI > 27 with
comorbidity



Pharmacotherapy

10-25% weight loss

Prescriptive Nutritional Intervention


5-10% weight loss

Lifestyle Modification

2-5% weight loss




The reality of treatment doesn't match the best practice






Discussion, Diagnosis, Direction are key for effective obesity management



Discussion

Bring up the matter of weight and weight management in interactions



Diagnosis

Communicate the diagnosis of obesity to the patients, and note it in the patient's records



Direction

Provide guidance and schedule follow-up appointments specifically for weight management



When beginning the discussion with your patient, start with patient-first language and shared decision making

“People-first” language recognizes the potential hazards of referring to or labeling individuals by their disease. Thus, “patient who has pre-obesity or obesity” or “patient with overweight or obesity” are preferred over “obese patient.” This is similar to the standard with other diseases, such as cancer, wherein “patient with cancer” is preferred over “cancerous patient.”

Encouraged Terms

- Weight
- Excess weight
- Unhealthy weight
- Overweight
- Body mass index
- Affected by obesity

Discouraged Terms

- Morbidly obese
- Obese
- Fat
- Heaviness
- Large size



What shared decision making looks like

- One or more clinicians share with the patient information about relevant testing or treatment options, including the severity and probability of potential harms and benefits and alternatives of these options given the specific nature of the patient's situation;
- The patient explores and shares with the clinician(s) his or her preferences regarding these harms, benefits, and potential outcomes; and
- Through an interactive process of reflection and discussion, the clinician(s) and patient reach a mutual decision about the subsequent treatment or testing plan.






Making shared decision making practical

Pt Goals	Favors Lifestyle	Favors Medication	Favors Surgery
Needs > 20% weight loss	-	++	+++
Needs/wants diabetes resolution/remission	+/-	+	+++
Needs/wants fatty liver disease resolution (>10%)	+	++	+++
Needs/wants to prevent diabetes	++	+++	+++
No complications of obesity, wants weight loss	+++	++	+
Wants to be free of medication	++	-	+++



Patient example of shared decision making

- Initially recommended surgery
- Pt decided medication route
- Now on 4 meds and wants to have surgery to get off meds!
- Hard to predict the future





Remember: how you partner with your patient matters!

55% cancel appointments out of weight-related anxiety


69% experience weight-related stigma from physician

52% women report weight as barrier to care

67% medical students endorse weight bias



Now that you've engaged in shared decision making with the patient, let's talk pharmacotherapy (1/2)



■ Drugs@FDA: FDA-Approved Drugs. Accessed April 14, 2021. <https://www.accessdata.fda.gov/scripts/cder/daf/>.



Now that you've engaged in shared decision making with the patient, let's talk pharmacotherapy (2/2)

Lifestyle Modification
Prescriptive Nutritional Intervention
Surgery
Pharmacotherapy
Devices

Gold shading = injection

Weight loss %	% of patients in behavior programs (WW®, IBT)	% of patients in Virta® program	% of patients with surgery at 10 years	% of patients on tirzepatide 15mg once a week	% patients on semaglutide 2.4 mg weekly	% patients on liraglutide 3 mg daily (Plus IBT)	% patients on phentermine topiramate 15/92 mg	% patients on bupropion/naltrexone (Plus IBT)	Gelesis -100
>5%	48%	74%	96.6%	96%	90%	63% (74%)	67%	42% (66%)	58.6%
>10%	25%	49%	>80%	90%	75%	33% (52%)	47%	21% (41%)	27.2%
>15%	12%			78%	56%	(36%)	32%	10% (29%)	
>20%	10%		72%	63%	36%		15%		
>30%	4%		40%	23%					



Choosing the Medication

Is it covered by insurance?

- Medicare does not cover AOMs
- Medicaid is state dependent and does not currently cover in MA (does in RI and NH)
- Phentermine, topiramate, bupropion, naltrexone, GLP-1

Assess for contraindications/risks

- GLP-1 - pancreatitis
- Topiramate - kidney stones, severe depression
- Phentermine – cardiovascular risk, anxiety, bipolar d/o
- Bupropion – seizure disorder
- Naltrexone – opioid use

Assess for double benefits

- Topiramate for migraine or BED
- Bupropion for depression/ADHD


Does patient have diabetes, prediabetes or insulin resistance

- Consider metformin, SGLT-2 and GLP-1 first
- Off label use of GLP-1 with semaglutide, liraglutide or covered GLP-1




Semaglutide 2.4mg

Semaglutide 2.4 mg demonstrates sustained weight loss versus placebo and a 17.4% weight loss after 68 weeks in the STEP 4 trial




https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2301466.html

C In-Trial Data at Wk 68






Effect of Once-Weekly Tirzepatide, as Compared with Placebo, on Body Weight






Remember: Treatment is Chronic




No. of participants

Semaglutide run-in	803	801	803	802	800					
Continued semaglutide			535	527	531	525	523	521	515	518
Switched to placebo			268	266	264	258	259	254	245	248




No. of participants

Semaglutide run-in	803	803	803	802	801					
Continued semaglutide			535	527	531	525	522	522	515	518
Switched to placebo			268	267	265	258	258	254	246	248



No. of participants


Semaglutide run-in	803	803	803	802	801					
Continued semaglutide			535	527	531	525	523	521	516	520
Switched to placebo			268	267	265	258	260	254	246	250






20 weeks of semaglutide run-in + 48 weeks of continued semaglutide, 2.4 mg/wk (n=520)
 20 weeks of semaglutide run-in + 48 weeks of placebo (n=250)



Create an obesity care plan





Q&A





Reach out for help!